Latanoprost

Summary

Latanoprost (CHEMBL1051) is an approved small-molecule antiglaucoma drug (ATC S01EE01) targeting PTGFR; indicated across 7 conditions including open-angle glaucoma and ocular hypertension.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01EE01
• Targets: 1 (PTGFR)
• Indications: 7 conditions
• Clinical trials: 154
• Chemistry: 432.6 Da · C26H40O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1051
Name	Latanoprost
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5311221
ChEBI	CHEBI:6384
ATC	S01EE01
Molecular formula	C26H40O5
Molecular weight	432.6
InChIKey	GGXICVAJURFBLW-CEYXHVGTSA-N

SMILES: CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O

IUPAC name: propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate

ChEBI definition: A prostaglandin Fα that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.

Pharmacological roles (ChEBI): antiglaucoma drug, antihypertensive agent, EC 4.2.1.1 (carbonic anhydrase) inhibitor, prodrug.

Also known as: Catiolanze, Iyuzeh, Latanoprost, Latanoprost (isopropyl ester), Latanoprost component of rocklatan, Latanoprost component of xalacom, Monopost, PHXA-41, PHXA41, T-2345, T2345, XA-41

Patent coverage: 3,721 distinct patent families (14,975 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGFR	FP receptor	Full agonist	6.3	0%	P43088

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Menin/Histone-lysine N-methyltransferase MLL, Mitogen-activated protein kinase 1, Bile salt export pump.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPT	5.3	Potency	5012	nM	CHEMBL_ACT_4012935

Target pathways

Aggregated over 1 target gene(s): PTGFR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGFR
G alpha (q) signalling events	1	PTGFR

Dominant GO biological processes

GO term	Targets
inflammatory response	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
positive regulation of cytosolic calcium ion concentration	1
parturition	1
positive regulation of cell population proliferation	1
positive regulation of gene expression	1
response to estradiol	1
response to lipopolysaccharide	1
negative regulation of apoptotic process	1
cellular response to prostaglandin D stimulus	1
signal transduction	1
response to lipid	1

Indications & clinical

Indications

7 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
open-angle glaucoma	4	MONDO:0005338	EFO:0004190
ocular hypertension	4	MONDO:0006875	EFO:1001069
hypertensive disorder	4	MONDO:0005044	EFO:0000537
glaucoma	4	MONDO:0005041	MONDO:0005041
Meniere disease	2	MONDO:0007972	EFO:0006862
vitiligo	2	MONDO:0008661	EFO:0004208
alopecia areata	1	MONDO:0005340	EFO:0004192

Clinical trials

Total trials: 154.

Phase distribution

Phase	Trials
PHASE4	55
PHASE3	32
PHASE2	29
Not specified	19
PHASE1	7
PHASE1/PHASE2	6
PHASE2/PHASE3	3
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04957329	PHASE4	RECRUITING	Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
NCT06883123	PHASE4	RECRUITING	Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
NCT07048886	PHASE4	NOT_YET_RECRUITING	Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)
NCT07325240	PHASE4	RECRUITING	24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
NCT07465913	PHASE4	RECRUITING	Rocklatan vs Latanoprost Post-DSLT
NCT00140062	PHASE4	COMPLETED	Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
NCT00224289	PHASE4	COMPLETED	Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
NCT00273429	PHASE4	COMPLETED	Cosopt Versus Xalatan
NCT00273481	PHASE4	COMPLETED	Cosopt Versus Xalacom
NCT00304785	PHASE4	COMPLETED	Latanoprost Versus Fotil
NCT00308945	PHASE4	COMPLETED	Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients
NCT00329095	PHASE4	COMPLETED	An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00330577	PHASE4	COMPLETED	24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
NCT00348400	PHASE4	COMPLETED	Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
NCT00440141	PHASE4	COMPLETED	Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
NCT00539526	PHASE4	COMPLETED	Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
NCT00541242	PHASE4	COMPLETED	Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00647101	PHASE4	COMPLETED	A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
NCT00705757	PHASE4	COMPLETED	The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
NCT00735449	PHASE4	COMPLETED	Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
NCT00757835	PHASE4	COMPLETED	24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
NCT00759941	PHASE4	COMPLETED	A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin
NCT00796198	PHASE4	UNKNOWN	Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure
NCT00798694	PHASE4	COMPLETED	How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
NCT00799682	PHASE4	COMPLETED	Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
NCT00811564	PHASE4	COMPLETED	An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
NCT00847483	PHASE4	COMPLETED	Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US
NCT00906594	PHASE4	COMPLETED	Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure
NCT00913029	PHASE4	COMPLETED	Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)
NCT00941525	PHASE4	COMPLETED	Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure
NCT01151904	PHASE4	TERMINATED	Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
NCT01155219	PHASE4	COMPLETED	Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
NCT01162603	PHASE4	COMPLETED	Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)
NCT01225653	PHASE4	COMPLETED	Topical Application of Latanoprost in Diabetic Retinopathy
NCT01243567	PHASE4	COMPLETED	Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
NCT01315574	PHASE4	TERMINATED	Effects of Anti-Glaucoma Medications on the Ocular Surface
NCT01448837	PHASE4	COMPLETED	24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
NCT01525173	PHASE4	COMPLETED	A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
NCT01655758	PHASE4	COMPLETED	24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
NCT01779284	PHASE4	COMPLETED	Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

13 molecules share ≥1 primary target. Top 13 by shared-target count:

Molecule	Source	Status	Shared targets
DINOPROST	ChEMBL + PubChem	Phase 4 (approved)	PTGFR
DINOPROSTONE	ChEMBL + PubChem	Phase 4 (approved)	PTGFR
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGFR
SEPETAPROST	ChEMBL	Phase 3	PTGFR
CLOPROSTENOL	ChEMBL + PubChem	Phase 2 (approved)	PTGFR
EBOPIPRANT	ChEMBL	Phase 2	PTGFR
FLUPROSTENOL	ChEMBL	Phase 2	PTGFR
Belzutifan	PubChem	Approved	PTGFR
Bimatoprost	PubChem	Approved	PTGFR
Grapiprant	PubChem	Approved	PTGFR
Latanoprostene Bunod	PubChem	Approved	PTGFR
Nitroglycerin	PubChem	Approved	PTGFR
Tafluprost	PubChem	Approved	PTGFR